The WHISTLE-PF clinical trial of ENV-101 (taladegib): Improving Lung Function for IPF Patients

Join us for this webinar as respirologist Dr. Giovanni Ferrara, describes the results of the phase 2a clinical trial of a new drug being developed by Endeavor BioMedicines, called ENV-101 (taladegib), for idiopathic pulmonary fibrosis (IPF). Learn how this treatment is improving lung function and how you can participate.

Sign up for the webinar below.
Live stream will start at 2PM EDT on June 10, 2025.